NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
Stocks in this Quantisnow insightHealth Care
Historical context for NBP
Across the 10 sessions after earlier NBP headlines, the stock closed higher 6 times and lower 4 times, with a median move of 4.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NBP | SPY |
|---|---|---|---|
| Mar 3, 2026 | NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 | -7.2% | -0.9% |
| Mar 2, 2026 | NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference | +5.2% | +0.1% |
| Feb 19, 2026 | NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform | +0.9% | -0.3% |
| Feb 18, 2026 | NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer | +2.2% | +0.5% |
| Feb 6, 2026 | H.C. Wainwright resumed coverage on NovaBridge Biosciences with a new price target | +11.1% | +1.9% |
| Jan 20, 2026 | NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei | +5.1% | -2.0% |
Quantisnow market dataNASDAQ
NBP
NovaBridge Biosciences
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for NBP
Full NBP profile on Quantisnow Follow NBP and get a push notification the moment its next story breaks.